Future Risks in Patients With Severe Asthma
Open Access
- 1 January 2019
- journal article
- review article
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 11 (6) , 763-778
Abstract
A major burden of severe asthma is the future risk of adverse health outcomes. Patients with severe asthma are prone to serious exacerbation and deterioration of lung function and may experience side effects of medications such as oral corticosteroids (OCSs). However, such future risk is not easily measurable in daily clinical practice. In particular, currently available tools to measure asthma control and asthma-related quality of life incompletely predict the future risk of medication-related morbidity. This is a significant issue in asthma management. This review summarizes the current evidence of future risk in patients with severe asthma. As future risk is poorly perceived by controlled asthmatics, our review focuses on the risk in patients with 'controlled' severe asthma. Of note, it is likely that long-term OCS therapy may not prevent future asthma progression, including lung function decline. In addition, the risk of drug side effects increases even during low-dose OCS therapy. Thus, novel treatments are highly desirable for reducing future risks without any loss of asthma control.Keywords
This publication has 77 references indexed in Scilit:
- Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthmaJournal of Allergy and Clinical Immunology, 2019
- Development and Validation of Personalized Prediction to Estimate Future Risk of Severe Exacerbations and Uncontrolled Asthma in Patients with Asthma, Using Clinical Parameters and Early Treatment ResponseThe Journal of Allergy and Clinical Immunology: In Practice, 2019
- Mortality: a neglected outcome in OCS-treated severe asthmaEuropean Respiratory Journal, 2017
- Long-term Systemic Corticosteroid Exposure: A Systematic Literature ReviewClinical Therapeutics, 2017
- Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe AsthmaNew England Journal of Medicine, 2017
- Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studiesThe Lancet Respiratory Medicine, 2016
- Risk of corticosteroid-related adverse events in asthma patients with high oral corticosteroid useAllergy and Asthma Proceedings, 2015
- Risk factors for death in patients with severe asthmaJornal Brasileiro de Pneumologia, 2014
- Clinical Burden and Predictors of Asthma Exacerbations in Patients on Guideline-based Steps 4-6 Asthma Therapy in the TENOR CohortThe Journal of Allergy and Clinical Immunology: In Practice, 2014
- Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbationJournal of Allergy and Clinical Immunology, 2011